Patrick Davol, MD
Urology · Medford, ORNPI 1003025875
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,881 of the $5,497 with a category attached, or 70.6%. 31 manufacturers reported payments, led by Procept Biorobotics Corporation at 31.0% of the total. Reporting peaked in 2024 at $2,062 and has fallen 85.5% since, to $299 in 2025.
Across 166 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$2K
- AbbVie$662
- Astellas Pharma US Inc$543
- Boston Scientific$542
- Coloplast$327
- Merck$244
- plus $1K from 25 others
What the payments were for
- Travel & lodging$1,48527%
- Food & beverage$3,88171%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 7 | $1,703 |
| AbbVie(2 entities) | 32 | $662 |
| Astellas Pharma US Inc | 26 | $543 |
| Boston Scientific | 23 | $542 |
| Coloplast | 9 | $327 |
| Merck | 7 | $244 |
| Intuitive Surgical | 4 | $204 |
| Ferring Pharmaceuticals Inc. | 5 | $135 |
| 180 Medical, Inc. | 4 | $129 |
| Pfizer | 7 | $123 |
| Bayer | 4 | $115 |
| Myriad Genetic Laboratories, Inc. | 6 | $114 |
| Johnson & Johnson | 4 | $88 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Myovant Sciences Inc. | 3 | $54 |
| Histosonics, Inc. | 2 | $51 |
| Endo Pharmaceuticals Inc. | 3 | $48 |
| Travere Therapeutics, Inc. | 3 | $41 |
| Olympus America Inc. | 1 | $40 |
| Ambu Inc. | 2 | $32 |
| Novartis | 1 | $30 |
| Cook Medical LLC | 1 | $28 |
| Urovant Sciences Inc | 1 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Endo USA, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$1,578
- TITAN$243
- LYNPARZA$120
- BOTOX$106
How this compares
$5,497 in reported general payments places this provider in the 80th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 14 | $191,583 |
| MyrbetriqMirabegron | 18 | $12,906 |
| Tamsulosin Hcl | 488 | $8,969 |
| GemtesaVibegron | 15 | $8,680 |
| Finasteride | 345 | $6,328 |
| Potassium Citrate ErPotassium Citrate | 72 | $5,400 |
| Silodosin | 72 | $3,881 |
| Testosterone Cypionate | 35 | $2,046 |
| Testosterone | 28 | $1,980 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,778 |
| NitrofurantoinNitrofurantoin Macrocrystal | 79 | $1,702 |
| Bicalutamide | 34 | $1,016 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 46 | $749 |
| Chlorthalidone | 40 | $567 |
| Oxybutynin Chloride | 34 | $492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $115 | $191,58314 claims |
| Astellas Pharma US IncMyrbetriq | $543 | $12,90618 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $65 | $8,68015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 153 urology providers in Oregon.
Other urology in Medford
- Kim ThaiMedford$57K
- Thong BuiMedford$3K
- James LoosMedford$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
- Amir PatelPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.